Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Crossroads Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$6,086,989

207 payments

Through program year 2025, Crossroads Clinical Research is reported as receiving $6,086,989 in research payments, across 207 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $579,235 29
2023 Research $294,652 23
2022 Research $2,136,008 74
2021 Research $2,156,425 50
2020 Research $854,177 15
2019 Research $66,491 16

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $3,543,288 116 payments
  2. Regeneron Pharmaceuticals, Inc. $2,387,824 47 payments
  3. AstraZeneca Pharmaceuticals LP $53,185 4 payments
  4. AbbVie, Inc. $38,186 21 payments
  5. AstraZeneca UK Limited $24,019 2 payments
  6. Rhythm Pharmaceuticals, Inc. $17,276 2 payments
  7. Acerus Pharmaceuticals Corporation $11,828 7 payments
  8. Novo Nordisk AS $7,543 2 payments
  9. Ironwood Pharmaceuticals, Inc $2,386 1 payment
  10. Pfizer Inc. $938 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age $1,438,560 16 payments
  2. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $1,160,788 23 payments
  3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $991,997 16 payments
  4. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $914,455 45 payments
  5. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $547,290 14 payments
  6. A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age $386,688 13 payments
  7. A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $235,040 8 payments
  8. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $182,177 12 payments
  9. A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia $77,204 6 payments
  10. A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults $44,643 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record